Acute skin GVHD following syngeneic BMT for CLL.
A 41-year-old woman received a syngeneic BMT for CLL and subsequently developed acute skin GVHD. Transfusion-related allogeneic GVHD was excluded on the basis of an unchanged HLA type in circulating lymphocytes. Short tandem repeat PCR was used to confirm syngeneicity between donor and recipient. The patient had a personal and family history of autoimmune disease which may have made her particularly susceptible to development of syngeneic GVHD. The distinction between allogeneic and syngeneic or autologous GVHD is important because of therapeutic implications.
Deane
M
M
Haematology Department, Royal Free Hospital and School of Medicine, London, UK.
Singer
C
C
Lawler
M
M
McElwaine
S
S
Gomez
K
K
Prentice
H G
HG
D000208:Acute Disease; D000328:Adult; D001853:Bone Marrow; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology*; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000628:therapy*; D012871:Skin Diseases / Q000276:immunology; D018183:Transplantation Chimera; D014185:Transplantation, Isogeneic / Q000009:adverse effects* / Q000276:immunology*